Donanemab removes Alzheimer's plaques: what is special about its target?
- PMID: 36097986
- DOI: 10.1016/S2666-7568(21)00144-6
Donanemab removes Alzheimer's plaques: what is special about its target?
Conflict of interest statement
NCF has served as a consultant, on advisory boards, or on a data-monitoring committee for Roche, Biogen, and Ionis. HZ has served on scientific-advisory boards for Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, and CogRx, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, and Biogen, and is a cofounder of Brain Biomarker Solutions in Gothenburg AB (also known as BBS), which is part of the GU Ventures Incubator Programme. DOTA and AJH declare no competing interests.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
